). AP uptake data also supported the presence of saturable and nonsaturable components (K m ~0.9 mM, V max ~330 pmol min -1 mg protein -1 , and K d, uptake ~0.04 µL min -1 mg protein -1 ). BL efflux was rate-limiting to transcellular transport of metformin; AP efflux was 7-fold greater than BL efflux and was not inhibited by GW918, a P-gp inhibitor. AP efflux was transstimulated by metformin and prototypical substrates of organic cation transporters (OCTs), suggesting that a cation-specific bidirectional transport mechanism mediated the AP efflux of metformin. BL efflux of intracellular metformin was much less efficient in comparison with the overall transport, with BL efflux clearance accounting for ~7% and ~13% of the overall transport clearance at 0.05 mM and 10 mM metformin concentrations, respectively. Kinetic modeling of cellular accumulation and transport processes fits the data and supports the finding that transport occurs almost exclusively via the paracellular route (~90%) and that the paracellular transport is saturable. This report provides strong evidence of a saturable mechanism in the paracellular space and provides insight into possible mechanisms for the dose-dependence of metformin absorption in vivo.
This article has not been copyedited and formatted. The final version may differ from this version. Metformin is an oral antihyperglycemic agent that has been widely used in the management of non-insulin-dependent diabetes mellitus. The oral bioavailability of metformin ranges between 40% and 60%; it is primarily excreted unchanged in the urine, with negligible metabolism (Tucker et al., 1981; Scheen, 1996) ; approximately 20-30% of the dose is recovered in the feces unchanged (Tucker et al., 1981; Vidon et al., 1988) .
The oral absorption of metformin is high considering its hydrophilic nature (e.g.
calculated log D -6.13 at pH 7) (Saitoh et al., 2004) and net positive charge at intestinal pH values (pKa 13.8) (Fig. 1 ). It is believed to be predominantly absorbed in the upper part of the intestine, and estimated time for its complete absorption is approximately 6 h (Tucker et al., 1981; Scheen, 1996) . The elimination half-life after oral administration of metformin is more likely a reflection of the rate of absorption than true elimination of the drug (Tucker et al., 1981) . In other words, metformin exhibits flip-flop kinetics where the slow absorption of metformin is the rate-limiting factor in its disposition.
Clinical trials with metformin have demonstrated decreased bioavailability at higher doses, suggesting saturable intestinal absorption (Noel, 1979; Tucker et al., 1981; Sambol et al., 1996; Scheen, 1996) . When metformin was co-administered orally with the histamine H 2 -receptor antagonist cimetidine, metformin plasma concentrations were increased and renal tubular secretion was decreased, implying a role of the organic cation transporters in metformin elimination (Somogyi et al., 1987) . However, in the same study, a significant change in metformin absorption due to cimetidine co-administration was not observed, as determined by total urinary recovery of metformin, suggesting no interactions associated with their intestinal absorption. Recent work with single-pass intestinal perfusion in rats with metformin showed that permeability in the duodenum This article has not been copyedited and formatted. The final version may differ from this version. was concentration-dependent, suggesting the involvement of a carrier-mediated saturable mechanism (Song et al., 2006) . Conversely, another study concluded that there was a dose-independent linear absorption of metformin in rats (Choi et al., 2006) , although the doses used in this study were high (50-200 mg/kg), thus potentially saturating any carriermediated absorption over the dose range examined. It is clear that the mechanisms responsible for the dose-dependent absorption of metformin in humans need to be better understood.
Metformin is a substrate for organic cation transporters (OCTs) in both the kidney (OCT2) (Kimura et al., 2005a; Kimura et al., 2005b; Terada et al., 2006) and the liver (OCT1) (Wang et al., 2002; Kimura et al., 2005a) . Oct1 also was implicated in the intestinal secretion of metformin following IV administration in mice (Wang et al., 2002) . Detectable message levels for hOCT1, hOCT2, hOCT3, hOCTN1, and hOCTN2
have been found in human intestinal tissue (Ming et al., 2005; Muller et al., 2005; Englund et al., 2006; Seithel et al., 2006) . In addition, metformin has been identified as a substrate for the multidrug and toxin extrusion (MATE) antiporters, MATE1 and MATE2-K (Masuda et al., 2006; Terada et al., 2006; Tsuda et al., 2007) . Although MATE2-K, a kidney specific isoform, is believed to be involved in metformin elimination (Masuda et al., 2006) , the role of MATE antiporters on metformin absorption is unknown. Metformin is also a substrate for the newly identified proton-coupled transporter, the plasma-membrane monoamine transporter (PMAT) , that has been localized on the apical membrane of human epithelial cells and may facilitate metformin absorption (Zhou et al., 2007) .
This article has not been copyedited and formatted. The final version may differ from this version. The present study was undertaken to elucidate the transport mechanisms involved in the intestinal absorption of metformin. The approach used was similar to the one used to recently elucidate the absorptive mechanism of another hydrophilic cation, ranitidine . The current studies reveal a complex transport mechanism that involves the interaction of metformin with AP uptake and efflux transporters and also a paracellular transport mechanism. The postulated mechanism(s) of metformin transport helps to explain the saturable, dose-dependent absorption of metformin observed in humans.
This article has not been copyedited and formatted. The final version may differ from this version. 
METHODS

Materials
The Caco-2 cell line was obtained from ATCC (Manassas, VA, USA 
Cell Culture
Caco-2 cells were cultured at 37ºC in EMEM with 10% FBS, 1% NEAA, and 100 U/ml penicillin, 100 µg/mL streptomycin, and 0.25 µg/mL amphotericin B in an atmosphere of 5% CO 2 and 90% relative humidity. The cells were passaged following 90% confluency using trypsin-EDTA, and plated at a 1:5 ratio in 75-cm 2 T flasks. 
Transport Studies
Transport studies involved only AP to BL (absorptive) direction, and were conducted as described previously with minor deviations .
Cell monolayers were preincubated with transport buffer solution (HBSS with 25 mM Dglucose and 10 mM HEPES), pH 7.2) for 30 min at 37ºC. The donor (AP) compartment was replaced with 0.4 mL of transport buffer containing various concentrations of [ 14 C]metformin with or without 0.2 mM quinidine for absorptive transport. The pH in both AP and BL compartments was maintained at 7.2 for all transport studies.
Appearance of metformin in the receiver (BL) compartment was monitored as a function of time in the linear region of transport and under sink conditions. For experiments examining the role of cation selective uptake, cell monolayers were preincubated in the absence or presence of quinidine (0.2 mM) in the AP compartment for 30 min. At the conclusion of the experiment, cellular accumulation was determined following washing with 4ºC transport buffer three times in each compartment. After this, the cell monolayers were allowed to dry, excised from the insert, and placed in 300 µL of 1%
Triton-X100 for 3 hours, while shaking. The solution was then centrifuged at 10,000 rpm for 10 min and the supernatant was analyzed. [ 14 C]Metformin in the receiver compartment and in the cellular compartment was measured using liquid scintillation This article has not been copyedited and formatted. The final version may differ from this version. 
Uptake Kinetics
All uptake studies were conducted using methods previously reported with minor deviations . Caco-2 cell monolayers were preincubated for 30 min in transport buffer. Experiments were initiated by replacing the donor compartment (0.4 mL for AP and 1.5 mL for BL) with transport buffer containing various concentrations of [ 14 C]metformin. Uptake was determined over 5 min and 30 min (the linear uptake region) for AP and BL uptake respectively. The pH in both AP and BL compartments was 7.2 for all uptake experiments. Cell monolayers were washed three times with 4ºC transport buffer and metformin cellular accumulation and protein content was measured as described under "Transport Studies".
Efflux Studies:
Cell monolayers were preincubated in transport buffer at 37ºC for 30 min, after which they were preloaded from the AP side for 60 min with 0.5 mM [ 14 C]metformin.
The cells were then washed three times with 4ºC transport buffer, placed in contact with 
Data Analysis
Transport of metformin is expressed in terms of apparent permeability (P app ) and is described by the following equation:
where dX/dt is the mass of metformin (X) transported over time (t), A is the surface area of the Transwell™ porous membrane insert, and C o is the initial concentration in the donor compartment. Similarly, transport can be expressed as flux and is described by the following equation:
where C is the metformin concentration, J max is the maximal flux, K m is the MichaelisMenten constant, and K d, transport is the nonsaturable component of transport.
Uptake data were fit to a model describing one saturable and one nonsaturable component (Eq. (3B))
where C is the metformin concentration, V max is the maximal velocity, K m is the Michaelis-Menten constant, and K d, uptake is the nonsaturable component of uptake.
Clearance (CL) values for efflux across both membrane barriers (e.g. AP and BL) and transport of metformin form the AP to BL compartment were calculated using Eq.
:
where dX/dt represents the mass of metformin (X) effluxed or transported over time (t) 
Mathematical Model
A compartmental modeling approach was implemented to examine the accumulation and transport of metformin in Caco-2 cells as described previously . The three-compartment model structure can be seen in Fig 
where X 1 , X 2 , and X 3 represent the mass of drug in the AP, cellular, and BL compartments, respectively. First-order rate constants (min -1 ) signify parameters estimates for BL efflux (k 23 ) and BL uptake (k 32 ) were fixed during modeling using experimentally derived values to allow for more accurate estimation of the remaining parameters. BL efflux (k 23 ) was calculated from the following equation:
where X is the mass of metformin effluxed into the BL compartment as a function of time (t) and X o is the initial mass following preloading of the cells. AP and BL uptake rate constants were calculated using the equation for uptake rate in terms of the experimentally derived kinetic parameters reported previously .
The rate constants (k 12 and k 32 ) were calculated by using the kinetic parameters (V max , K m , and K d, uptake ) associated with AP and BL uptake. The initial rate of uptake into the cellular compartment (e.g. X 2 ) is described by the following equation:
where dX 2 /dt initial is the initial rate of uptake of metformin mass (X) into the cell. The initial rate of metformin uptake rate also can be described by a model containing one saturable and one nonsaturable component, Eq. (3B). By expressing metformin concentration in terms of mass (X) divided by the donor compartment volume (V AP (or BL) ), the initial uptake rate is represented in the following equation as:
where V max is the maximal velocity, K m is the Michaelis-Menten constant, K d, uptake is the nonsaturable component of uptake, and V AP (or BL) is the volume of the donor This article has not been copyedited and formatted. The final version may differ from this version. 
where V max values and K d values were multiplied by the average protein content of the monolayers (0.20 mg protein on a 1 cm 2 Transwell™ insert) to remove the dependency of protein content from the uptake rate constants. All data are expressed as mean ± SD from three measurements. Statistical significance was evaluated using unpaired t tests.
Validation of the model and goodness of fit were assessed by the %CV values for each parameter estimate, parameter sensitivity, and correlation matrices.
Simulation of Transcellular and Paracellular Transport
The transcellular and paracellular contributions to transport of metformin were determined by implementing parameter estimates from the modeling exercises and simulating the appearance of metformin in the receiver (BL) compartment using subsets of the differential equations, Eq. (5-7), containing rate constants that describe solely transcellular and paracellular transport. The equations for the simulations were:
Paracellular:
Transcellular:
RESULTS
Absorptive Transport and Apical Cellular Uptake of Metformin as a Function of
Concentration in Caco-2 Cell Monolayers
The absorptive transport across Caco-2 monolayers of metformin and its AP uptake as a function of concentration are shown in Figure 3 . For clarity, absorptive transport (subsequently referred to as "transport") refers to movement of drug from the AP compartment across the cell monolayer and into the BL compartment. Uptake and efflux will refer to movement of drug across only one membrane barrier (AP or BL).
Metformin transport was linear up to 90 min with less than 1% of metformin transported at all concentrations. The apparent permeability (P app ) decreased from 4.7 ± 0.2 nm sec -1 at 10 µM to 2.1 ± 0.3 nm sec -1 at 5 mM, providing evidence for saturable transport of metformin across Caco-2 monolayers (Fig. 3A , left axis). The transport, in terms of flux (J), was modeled as a function of metformin donor concentration (Fig. 3A , right axis).
The transport vs. concentration data were best fit to a model containing one saturable and one nonsaturable component (refer to Eq. (3A) in Methods). This model was previously fit to describe the transport of hydrophilic cations, ranitidine and famotidine (Lee and Thakker, 1999 Metformin (0.5 mM) AP uptake was rapid, but failed to reach steady state by 45 minutes (inset of Fig. 3B ). The initial AP uptake rate (determined over 5 min, the linear region of AP uptake) of metformin as a function of concentration was described by a model with one saturable and one nonsaturable component (Fig. 3B) . The V max and apparent K m estimated for AP metformin uptake were 331 ± 68 pmol min -1 mg protein -1 and 0.9 ± 0.2 mM, respectively ( suggests that ~90% of the overall metformin uptake at low concentrations (<< K m ) is via a saturable process (Table 1 ). The data are consistent with a saturable, carrier-mediated AP uptake process for metformin in Caco-2 cells.
Metformin BL uptake into Caco-2 cells was significantly lower than AP uptake, and was linear up to 30 min (data not shown). BL uptake kinetic parameters (V max and K m ) were obtained from concentration dependence of BL uptake in the linear range of BL uptake (30 min) from 0.01 to 5 mM dosing concentrations (Table 1) . BL uptake data did not support the incorporation of a term for nonsaturable uptake (K d, uptake ), as was observed previously for ranitidine BL uptake 
AP and BL Efflux of Metformin from Preloaded Cell Monolayers
A comparison of the AP uptake to transport suggests that the saturable AP uptake clearance is far more efficient than the saturable transport clearance of metformin ( Table   1 ), suggesting that BL efflux out of the cell may limit transcellular transport. To investigate the rate of efflux from the cell, appearance of metformin in the AP and BL compartments from cells preloaded with 0.5 mM [ 14 C]metformin was monitored as a function of time over the linear region (up to 90 min) of efflux ( Fig. 4A ). Metformin exhibited 7-fold higher AP efflux clearance than the BL efflux clearance, suggesting that the efflux across the AP membrane is assisted by an efflux transporter and that BL efflux is inefficient. The polarity between AP and BL efflux clearance values indicates that the BL membrane is rate limiting to transcellular transport. The AP efflux was not inhibited by 1 µM GW918, a P-glycoprotein (P-gp) inhibitor (Hyafil et al., 1993) (Fig. 4B ), thus ruling out the role of P-gp in the AP efflux of metformin; however, AP efflux was significantly inhibited by quinidine (p<0.001). This result supports previous reports that metformin is not a substrate for P-gp (Song et al., 2006) .
Trans-stimulation experiments have been conducted previously to determine
whether there is a bidirectional carrier-mediated efflux mechanism for other small molecules (Villalobos and Braun, 1998; Mizuuchi et al., 1999; Zhang et al., 1999; . Therefore, trans-stimulation of metformin efflux by (Fig. 4C ).
Inefficient Basolateral Efflux Limits Transcellular Transport of Metformin across
Caco-2 Cell Monolayers.
Transcellular transport of hydrophilic cations like metformin requires vectoral transport, comprised of both AP uptake and BL efflux from the cell. In Caco-2 cells, AP uptake of metformin is highly efficient ( 10 mM (Fig. 5A) . The ~26 fold increase in BL efflux rate correlated with the increase in estimated intracellular metformin concentration (C o ), which increased from 0.19 ± 0.02 mM to 4.93 ± 0.19 mM (~26 fold increase) as the loading concentration increased from 0.05 to 10 mM (inset of Fig. 5B ). The BL efflux rates for 0.05 and 10 mM loading concentrations could only account for ~25% and ~6% of the overall transport, respectively (Fig. 5A ). This result leads to the conclusion that metformin transport must occur predominantly via the paracellular route.
Transport ( (Fig. 6A, D respectively). Cellular accumulation describes the mass of drug accumulated in the cell at a fixed period of time. This value takes into account multiple processes, e.g. uptake and efflux, at both the AP and BL membranes. The cellular accumulation of metformin exceeded the transport throughout the experiment (Fig. 6A) , confirming that the uptake into the cell was not the rate limiting step to transport of metformin. In the presence of quinidine, the cellular accumulation and transport decreased significantly compared to control, and the cellular accumulation failed to exceed the amount of metformin transported (Fig. 6D ).
Kinetic modeling of the transport and cellular accumulation data was performed using the model outlined in Figure 2 with fixed experimentally derived parameters (k 23 ) and (k 32 ), representing BL efflux rate constant and BL uptake rate constant, respectively.
BL efflux rate constant (k 23 ) was fixed because BL efflux was linear over the 90 min (Fig. 4A ) and the clearance remained unchanged irrespective of cellular concentrations (Fig. 5B) . BL uptake rate constant (k 32 ) was calculated from V max and K m parameters experimentally derived (Table 1) , although this rate constant should play a negligible role in metformin disposition due to low concentrations of metformin in the BL compartment, e.g. <1% dose transported after 90 min. When assessing model goodness of fit, the estimate for AP uptake rate constant (k 12 ) was highly correlated with the AP efflux rate This article has not been copyedited and formatted. The final version may differ from this version. Parameter estimates were generated from simultaneously modeling the cellular accumulation and transport of metformin (0.05 mM) in the presence or absence of the cation transporter inhibitor, quinidine (0.2 mM) ( Table 2 ). In the presence of quinidine, the rate constant associated with AP uptake (k 12 ) decreased by approximately 90%, which was consistent with the inhibition of carrier-mediated uptake process and subsequent decrease in cellular accumulation of metformin (Table 2 , Fig. 6D ). Inhibition by quinidine caused a 3 fold decrease in apparent permeability (P app, total ) and a 7 fold decrease in cellular accumulation of metformin (Fig. 6D) . The paracellular rate constant (k 13 ) decreased by approximately 50% in the presence of quinidine ( Table 2 ). The ability of quinidine to decrease both transcellular and paracellular transport of a hydrophilic cation, ranitidine, has been observed previously .
Relative Contribution of Transcellular and Paracellular Transport Pathways to Absorptive Transport of Metformin
The relative contribution of paracellular and transcellular transport to the overall transport of metformin (0.05 mM) were estimated to be 9% and 91%, respectively (Table   This article (Table 3 ). Model predictions showed that the decrease in the permeability was likely due to a decrease in both transcellular permeability (P app, trans ) and paracellular permeability (P app, para ). In the presence of quinidine, the predicted relative contributions of transcellular and paracellular transport were estimated to be 3% and 97%, respectively (Table 3 ).
The relative contribution of transcellular and paracellular transport was estimated at three widely separated metformin concentrations: 0.05 mM (near the apparent K m for absorptive transport and below apparent K m for AP uptake), 0.5 mM (above apparent K m for absorptive transport and near the apparent K m for AP uptake), and 10 mM (above apparent K m for both transport and AP uptake). The P app, total values for metformin at 0.05, 0.5, and 10 mM were 5.0 ± 0.57, 3.9 ± 0.56, and 1.4 ± 0.24 nm sec -1 , respectively (Table 3) , showing a decrease with concentration. Cellular accumulation of metformin did not reach steady state by 90 min at both the 0.05 and 0.5 mM concentrations, while at the 10 mM metformin concentration steady state concentration in the cell appeared to be achieved at ~90 min (Fig. 6C ).
Kinetic modeling yielded parameter estimates that described the transport and accumulation data ( Table 2) . The model fit to the experimental data is presented in Fig. 6A-C. The experimental P app, total was in good agreement with the model predicted P app, This article has not been copyedited and formatted. The final version may differ from this version. increase in metformin donor concentration, which is consistent with a saturable AP uptake mechanism (Table 2 ). The rate constant estimates for paracellular transport (k 13 ) decreased with increasing metformin donor concentrations (Table 2) . For all three concentrations, the majority (~90-95%) of the metformin transport was estimated to be via the paracellular route, with only ~5-10% of the transport through the transcellular mechanism (Table 3 ). Both the predicted P app, trans and predicted P app, para decreased significantly with increasing metformin concentration ( did not change significantly from control (P app 5.8 ± 0.7 nm sec -1 ) in the presence of 0.05, 0.5, and 10 mM metformin or in the presence of quinidine (Table 3) .
DISCUSSION
The transport and AP uptake of metformin in Caco-2 cell monolayers contain saturable components (Fig. 3A,B) . To our knowledge, this is the first report of dosedependent transport of metformin in a cell-based in vitro system. The saturable component did not appear to play a dominant role in the transport of metformin, particularly at high concentrations (Fig. 3A, right Table 1 ). This discrepancy between the kinetic parameters for the transport and AP uptake suggests that the dose-dependent transport of metformin was not mediated solely by the AP uptake mechanism and associated transcellular processes.
The AP uptake and cellular accumulation of metformin appeared to reach steady state at 90 min for 10mM donor concentration (Fig. 6C ), but not for 0.05 and 0.5mM donor concentrations (Fig. 6A,B) . The inability to achieve steady-state over 90 min at 0.05 and 0.5 mM was surprising considering that the hydrophilic cation ranitidine (0.5 mM) achieved steady-state cellular concentrations at ~15 min . This was likely due to both restricted BL efflux and the presence of an efficient and high capacity bidirectional transport mechanism on the AP membrane.
This article has not been copyedited and formatted. The final version may differ from this version. Both AP uptake and cellular accumulation of metformin were strongly inhibited by quinidine (Fig. 6D) , a potent inhibitor of OCTs (Bourdet et al., 2005; Kimura et al., 2005b) , MATE1 (Ohta et al., 2006) , and P-gp (Adachi et al., 2001 ). Further, transinhibition by quinidine caused over a 5 fold reduction in AP efflux, suggesting that the AP uptake and efflux may be OCT mediated. The AP efflux was subject to transstimulation by metformin and prototypical cation transporter substrates, TEA and MPP (Fig. 4B) , further supporting the involvement of one or more OCT transporters in AP uptake and efflux. Organic cation transporters on the AP membrane of intestinal epithelium, in particular OCT3, are facilitative transporters that have been shown to transport cations bidirectionally in conjunction with electrochemical gradient or membrane potential (Schneider et al., 2005) . Although the exact transporter(s) implicated are not known, these studies provide strong evidence supporting an "OCTlike" bidirectional uptake/efflux transport mechanism on the AP membrane in Caco-2 cells for metformin. To our knowledge, this the first report of metformin AP efflux from an intestinal cell model system.
In comparison to the AP efflux, the BL efflux of metformin was quite inefficient (Fig. 4A) , and appeared to occur via passive diffusion as evidenced by little change in the BL efflux clearance over a wide concentration range (Fig. 5B) . The inefficient BL efflux appeared to be the rate-limiting step for the transcellular transport of metformin, resulting in its accumulation in the cells over the 90 min transport experiments (Fig 6A-C) . These results provided an explanation for why transport would be predominantly paracellular although metformin was efficiently taken up into Caco-2 cells.
This article has not been copyedited and formatted. The final version may differ from this version. The results for the transport, uptake, and efflux kinetic experiments revealed that metformin traverses Caco-2 cell monolayers predominantly via a saturable paracellular mechanism. A kinetic modeling approach was employed to estimate the relative contributions of trans-and paracellular transport. The modeling provides a more complete evaluation of the processes associated with transport and is able to estimate the relative contributions of paracellular and transcellular transport for drugs under a variety of experimental conditions (e.g. different concentrations, presence of inhibitors). At 0.05 mM donor concentration, approximately 90% of the metformin transport is estimated to occur via the paracellular route, whereas only approximately 10% would occur via the transcellular pathway (Table 3 ). This was in excellent agreement with experimental transport and efflux data, where ~7% of the transport could be accounted for by BL efflux for 0.05 mM metformin donor concentration (Fig. 5B) .
The kinetic modeling supports the results that suggest that metformin is transported predominantly via the paracellular route. However, it is difficult to reconcile this with the experimental observation that the permeability is concentration-dependent (i.e. transport is saturable) in Caco-2 cells (Fig. 3A) . The apparent permeability values (P app, total ) of metformin decreased from 5.0 ± 0.57 nm sec -1 to 1.4 ± 0.24 nm sec -1 from a dose of 0.05 mM to 10 mM, most of which is attributed to a decrease in the paracellular permeability, P app, para (Table 3 ). The permeability of mannitol, a prototypical paracellular transport marker, remained unchanged in the presence of varying metformin concentrations (Table 3) . Therefore, the decrease in paracellular permeability is likely due to saturable interactions between metformin and a macromolecule, presumably a protein, in the paracellular space of Caco-2 cell monolayers, and not due to gross changes This article has not been copyedited and formatted. The final version may differ from this version. in the paracellular space or in the tight junctions. It has been postulated that a saturable paracellular mechanism may be due to a cation-selective saturable mechanism in the paracellular space involving charge-charge interactions (Lee and Thakker, 1999; . Further studies are required to elucidate the mechanisms of this saturable paracellular transport mechanism. Anionic amino acid residues of tight junction protein family, claudins, have been shown to confer cationic charge selectivity, i.e. Na + permeability, to the paracellular pathway (Colegio et al., 2002; Van Itallie et al., 2003) .
It can be postulated that metformin may saturate these anionic sites in the tight junction, restricting its own transport at high concentrations.
The data presented in this study on metformin provide the most convincing evidence for a saturable process in the paracellular space acting on a small molecule. The results further show that metformin is taken up into the cells across the AP membrane via a cation-selective transporter. Once inside the cell, it is effluxed poorly across the BL membrane but much more efficiently across the AP membrane, perhaps via an AP transporter that serves as a cation-exchanger. It has been shown that metformin bioavailability in humans was dose-dependent (Noel, 1979; Tucker et al., 1981; Sambol et al., 1996; Scheen, 1996) . In order for transcellular processes to account for the dosedependent absorption, vectoral transport of metformin must exist, in which both AP and BL transporters are needed to transport the drug from the lumen into the blood. Provided for ~90% of the transport of metformin across the Caco-2 cell monolayers. Based on these results, a hypothesis is formulated that attempts to relate the transport behavior of metformin in the Caco-2 cell culture model of intestinal epithelium to its likely behavior in human subjects (depicted as the "sponge effect" in Fig. 7 ) upon oral administration. It can be speculated that a portion of the metformin dose is sequestered in the enterocytes due to the lack of an efficient BL efflux transporter mechanism. In addition, metformin is prevented from AP efflux due to a higher lumenal concentration of the drug that maintains the net flow of drug in the inward direction. Some of the metformin dose is absorbed across the intestinal epithelium via the cation-selective facilitative diffusion in the paracellular space (Fig. 7A ). As the dose passes through the intestine, the luminal concentration decreases below the achievable intracellular concentrations of metformin, and AP efflux occurs via the bidirectional "OCT-like" transport mechanism. The effluxed dose of metformin can be absorbed across the paracellular space via the cationselective saturable mechanism or taken up back into the enterocytes (Fig. 7B) . At high doses, (≥ 850 mg or ≥ 20 mM luminal concentration) the transport mechanisms are saturated and thus a smaller fraction of administered doses would be absorbed via the saturable mechanism. The data presented in this report provide an explanation for why the fraction absorbed for metformin, one of the most widely prescribed drugs on the market, could fall from ~0.9 to ~0.4 as the dose is raised to 2.0 g in humans (Tucker et al., 1981) . Further studies to identify the exact mechanism(s) of the saturable paracellular process will lead to better understanding of how metformin and other small hydrophilic cations traverse and navigate through tight junctions and the effects this process has on their disposition. Conceivably, a saturable paracellular transport mechanism could be This article has not been copyedited and formatted. The final version may differ from this version. value. Data represent mean ± SD; n=3. *p<0.05 compared to control; **p<0.01 compared to control; ***p<0.001 compared to control. Data were fit simultaneously using the model equations detailed in "Methods" section. n/a: not applicable a k 23 was fixed during modeling of metformin varying donor concentrations and quinidine data sets using kinetic parameters derived experimentally from BL efflux data using Equation 8.
TABLES
b k 32 was fixed during modeling of metformin varying donor concentrations and quinidine data sets using kinetic parameters derived experimentally from BL uptake data as seen in Table 1 and Equation 11 .
c Quinidine (0.2 mM) was added to the AP donor compartment containing metformin (0.05 mM).
